3q26.2/EVI1 rearrangement is associated with poor prognosis in classical Philadelphia chromosome-negative myeloproliferative neoplasms

Barbui, 2011, Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet, J Clin Oncol, 29, 761, 10.1200/JCO.2010.31.8436 Saeidi, 2016, Myeloproliferative neoplasms: current molecular biology and genetics, Crit Rev Oncol Hematol, 98, 375, 10.1016/j.critrevonc.2015.11.004 Thiele, 2008, Myeloproliferative neoplasms, 31 Tefferi, 2015, Myeloproliferative neoplasms: a contemporary review, JAMA Oncol, 1, 97, 10.1001/jamaoncol.2015.89 Bose, 2016, The evolution and clinical relevance of prognostic classification systems in myelofibrosis, Cancer, 122, 681, 10.1002/cncr.29842 Ortmann, 2015, Effect of mutation order on myeloproliferative neoplasms, N Engl J Med, 372, 601, 10.1056/NEJMoa1412098 Cui, 2011, Myelodysplastic syndrome with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) has a high risk for progression to acute myeloid leukemia, Am J Clin Pathol, 136, 282, 10.1309/AJCP48AJDCKTHUXC Lundberg, 2014, Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms, Blood, 123, 2220, 10.1182/blood-2013-11-537167 Rogers, 2014, Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study, Haematologica, 99, 821, 10.3324/haematol.2013.096420 Sun, 2011, De novo acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification, Mod Pathol, 24, 384, 10.1038/modpathol.2010.210 Wang, 2015, Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors, Blood, 126, 1699, 10.1182/blood-2015-05-646489 Wang, 2016, Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy, Blood, 127, 2742, 10.1182/blood-2016-01-690230 Hussein, 2009, Conventional cytogenetics in myelofibrosis: literature review and discussion, Eur J Haematol, 82, 329, 10.1111/j.1600-0609.2009.01224.x De Braekeleer, 2015, 3q26.2/EVI1 rearrangements in myeloid hemopathies: a cytogenetic review, Future Oncol, 11, 1675, 10.2217/fon.15.64 Nucifora, 1997, The EVI1 gene in myeloid leukemia, Leukemia, 11, 2022, 10.1038/sj.leu.2400880 Haltrich, 2005, Identification of 3q21q26.2 syndrome by "multipoint" interphase FISH analyses in childhood myeloid leukemia, Magy Onkol, 49, 141 Shaffer, 2016 Gangat, 2011, DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status, J Clin Oncol, 29, 392, 10.1200/JCO.2010.32.2446 Yuasa, 2005, Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression, EMBO J, 24, 1976, 10.1038/sj.emboj.7600679 Soderholm, 1997, The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator, Leukemia, 11, 352, 10.1038/sj.leu.2400584 Peeters, 1997, Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26.2;p13) in myeloproliferative disorders, Cancer Res, 57, 564 Groschel, 2014, A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia, Cell, 157, 369, 10.1016/j.cell.2014.02.019 Stein, 2010, Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease, Nat Med, 16, 198, 10.1038/nm.2088 Fonatsch, 1994, Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26.2) or t(3;3)(q21;q26.2), Leukemia, 8, 1318 Kennedy, 2013, Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms, Blood, 121, 2725, 10.1182/blood-2012-10-464248 Mesa, 2005, Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases, Blood, 105, 973, 10.1182/blood-2004-07-2864 Groschel, 2015, Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways, Blood, 125, 133, 10.1182/blood-2014-07-591461 Lavallee, 2015, EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations, Blood, 125, 140, 10.1182/blood-2014-07-591529 Tam, 2009, The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course, Blood, 113, 4171, 10.1182/blood-2008-09-178541 Passamonti, 2010, A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment), Blood, 115, 1703, 10.1182/blood-2009-09-245837